Literature DB >> 7832758

Caldesmon mRNA splicing and isoform expression in mammalian smooth-muscle and non-muscle tissues.

A M Payne1, P Yue, K Pritchard, S B Marston.   

Abstract

The recent determination of the genomic sequence of human caldesmon indicates that eight caldesmon mRNA species could be generated by selection of exon 1 or 1', exon 3a or 3ab and/or exon 4. We used reverse transcriptase PCR to determine which transcripts were produced in human, rabbit and sheep artery, vein, lung, intestine, kidney and liver. In all tissues the same three transcripts were present: exons 1'-2-3a-5-6...13, exons 1'-2-3a3b-5-6-...13 and exons 1'-2-3a3b-4-5-6...13. Exon 1 was not present and exon 4 was only present when exon 3b was also present. Three protein isoforms of caldesmon can be distinguished by electrophoresis on high-porosity 6% polyacrylamide gel: 130 kDa, 120 kDa and 70 kDa. The 70 kDa isoform lacks the sequence encoded by exon 3b. We investigated whether the two high-molecular-mass isoforms correspond to the presence and absence of exon 4 using an antiserum specific to the sequence encoded by exon 4. Western-blotting and immunoprecipitation experiments showed that both the 130 kDa and the 120 kDa isoforms were expressed with and without the exon 4 sequence. We therefore propose that the molecular-mass heterogeneity arises from additional first exons, possibly with separate promoter regions, which have not yet been characterized in the genomic sequence.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7832758      PMCID: PMC1136382          DOI: 10.1042/bj3050445

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  32 in total

1.  Immunoreactive forms of caldesmon in cultivated human vascular smooth muscle cells.

Authors:  M A Glukhova; A E Kabakov; O I Ornatsky; T D Vasilevskaya; V E Koteliansky; V N Smirnov
Journal:  FEBS Lett       Date:  1987-06-29       Impact factor: 4.124

2.  Functional domain of caldesmon.

Authors:  A Szpacenko; R Dabrowska
Journal:  FEBS Lett       Date:  1986-07-07       Impact factor: 4.124

3.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

4.  Expression of high and low molecular weight caldesmons during phenotypic modulation of smooth muscle cells.

Authors:  N Ueki; K Sobue; K Kanda; T Hada; K Higashino
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

5.  Phosphorylation by casein kinase II affects the interaction of caldesmon with smooth muscle myosin and tropomyosin.

Authors:  N V Bogatcheva; A V Vorotnikov; K G Birukov; V P Shirinsky; N B Gusev
Journal:  Biochem J       Date:  1993-03-01       Impact factor: 3.857

6.  Smooth muscle caldesmon. Rapid purification and F-actin cross-linking properties.

Authors:  A Bretscher
Journal:  J Biol Chem       Date:  1984-10-25       Impact factor: 5.157

7.  Genomic structure of the human caldesmon gene.

Authors:  K Hayashi; H Yano; T Hashida; R Takeuchi; O Takeda; K Asada; E Takahashi; I Kato; K Sobue
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

8.  Caldesmon is a Ca2+-regulatory component of native smooth-muscle thin filaments.

Authors:  S B Marston; W Lehman
Journal:  Biochem J       Date:  1985-11-01       Impact factor: 3.857

9.  Purification of a calmodulin-binding protein from chicken gizzard that interacts with F-actin.

Authors:  K Sobue; Y Muramoto; M Fujita; S Kakiuchi
Journal:  Proc Natl Acad Sci U S A       Date:  1981-09       Impact factor: 11.205

10.  The mechanism of Ca2+ regulation of vascular smooth muscle thin filaments by caldesmon and calmodulin.

Authors:  C W Smith; K Pritchard; S B Marston
Journal:  J Biol Chem       Date:  1987-01-05       Impact factor: 5.157

View more
  7 in total

1.  Comparative histological analysis of anterior vaginal wall in women with pelvic organ prolapse or control subjects. A pilot study.

Authors:  Wassim Badiou; Guillaume Granier; Philippe-Jean Bousquet; Xavier Monrozies; Pierre Mares; Renaud de Tayrac
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-01-09

2.  Histochemical localization of caldesmon isoforms in colon adenocarcinoma and lymph node metastases.

Authors:  Christoph Köhler
Journal:  Virchows Arch       Date:  2011-05-29       Impact factor: 4.064

3.  Contractile properties and proteins of smooth muscles of a calponin knockout mouse.

Authors:  J D Matthew; A S Khromov; M J McDuffie; A V Somlyo; A P Somlyo; S Taniguchi; K Takahashi
Journal:  J Physiol       Date:  2000-12-15       Impact factor: 5.182

4.  Caldesmon inhibits nonmuscle cell contractility and interferes with the formation of focal adhesions.

Authors:  D M Helfman; E T Levy; C Berthier; M Shtutman; D Riveline; I Grosheva; A Lachish-Zalait; M Elbaum; A D Bershadsky
Journal:  Mol Biol Cell       Date:  1999-10       Impact factor: 4.138

5.  Differential expression of splicing variants of the human caldesmon gene (CALD1) in glioma neovascularization versus normal brain microvasculature.

Authors:  Ping-Pin Zheng; Anieta M Sieuwerts; Theo M Luider; M van der Weiden; Peter A E Sillevis-Smitt; Johan M Kros
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

6.  Genetic ablation of zyxin causes Mena/VASP mislocalization, increased motility, and deficits in actin remodeling.

Authors:  Laura M Hoffman; Christopher C Jensen; Susanne Kloeker; C-L Albert Wang; Masaaki Yoshigi; Mary C Beckerle
Journal:  J Cell Biol       Date:  2006-02-27       Impact factor: 10.539

7.  Proteomic analysis of Medulloblastoma reveals functional biology with translational potential.

Authors:  Samuel Rivero-Hinojosa; Ling San Lau; Mojca Stampar; Jerome Staal; Huizhen Zhang; Heather Gordish-Dressman; Paul A Northcott; Stefan M Pfister; Michael D Taylor; Kristy J Brown; Brian R Rood
Journal:  Acta Neuropathol Commun       Date:  2018-06-07       Impact factor: 7.801

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.